Results 111 to 120 of about 84,688 (355)

PLACE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN ARTERIAL HYPERTENSION THERAPY

Рациональная фармакотерапия в кардиологии, 2016
Angiotensin II receptor antagonists (ARA) established their position recently duet to new indications above arterial hypertension (HT). These are chronic heart failure, history of myocardial infarction, atrial fibrillation and metabolic syndrome ...
S. A. Boytsov, I. P. Kolos
doaj   +1 more source

Angiotensin II Receptor Subtypes and Cardiac Function [PDF]

, 2017
All the components of the renin-angiotensin system have been identified in the heart including the angiotensin II receptor subtypes AT1 and AT2 In the normal human heart, there is a decreasing receptor density from the right atrium to the left ventricle.
Brink, M., Bullock, G., De Gasparo, M., Erne, P., Rogg, H., Wang, L., Whitebread, S.   +6 more
core  

Genes and primary headaches: discovering new potential therapeutic targets [PDF]

, 2013
Genetic studies have clearly shown that primary headaches (migraine, tension-type headache and cluster headache) are multifactorial disorders characterized by a complex interaction between different genes and environmental factors.
De Martino, Paola, Gai, Annalisa, Gentile, Salvatore, Paemeleire, Koen, Pinessi, Lorenzo, Rainero, Innocenzo, Rubino, Elisa, Sarchielli, Paola, Vacca, Alessandro   +8 more
core   +3 more sources

Risk of Acute Kidney Injury Associated With Nephrotoxic Burden in Hospitalized Patients: A Scoping Review

Clinical Pharmacology &Therapeutics, EarlyView.
Limited evidence exists synthesizing the risk of acute kidney injury (AKI) associated with the concomitant administration of multiple nephrotoxic drugs, and even less examining the concept of nephrotoxic burden. The objective of this scoping review was to (1) identify definitions of nephrotoxic burden; (2) methods used to quantify (use of calculations)
Wafa Alatawi, Jessica L. Wallace, Dhakrit Rungkitwattanakul, Britney A. Stottlemyer, Tiffany L. Tran, Melanie Manis Reida, Sandra L. Kane‐Gill   +6 more
wiley   +1 more source

Peroxisome proliferator-activated receptors-alpha (PPAR-α) and chronic heart failure: Is there a reason to discuss the metabolic strategy of treatment?

Терапевтический архив, 2014
Despite improved prognosis in patients with heart failure (HF) treated with neurohumoral activation-suppressing drugs (such as angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, Β-adrenergic receptor antagonists, aldosterone ...
I V Zhirov, A V Zaseeva, V P Masenko, S N Tereshchenko   +3 more
doaj  

Arterial hypertension and coronary heart disease: the place of angiotensin II receptor antagonists

Кардиоваскулярная терапия и профилактика, 2012
The paper considers arterial hypertension and coronary heart disease as pathologies which share multiple pathogenetic mechanisms. The role of angiotensin II receptor antagonists (ARA) in the effective treatment of these diseases and in prevention of ...
E. O. Taratukhin
doaj   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Hypertension: Renin-Angiotensin-Aldosterone System Alterations [PDF]

, 2015
Blockers of the renin-angiotensin-aldosterone system (RAAS), that is, renin inhibitors, angiotensin (Ang)-converting enzyme (ACE) inhibitors, Ang II type 1 receptor antagonists, and mineralocorticoid receptor antagonists, are a cornerstone in the ...
Danser, A.H.J. (Jan), Esch, J.H.M. (Joep) van, Meiracker, A.H. (Anton) van den, Riet, L. (Luuk) te, Roks, A.J.M. (Anton)   +4 more
core   +1 more source

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source

Pharmacological Treatment for Atrial Fibrillation

Journal of Arrhythmia, 2005
Pharmacological treatment for atrial fibrillation has a variety of purposes, such as pharmacological defibrillation, maintenance of sinus rhythm, heart rate control to prevent congestive heart failure and prevention of both cerebral infarction and atrial
Kaoru Sugi, MD PhD, Mahito Noro, MD PhD, Takao Sakata, MD PhD, Naoki Tezuka, MD, Takeshi Nakae, MD, Kenta Kumagai, MD, Tsuyoshi Sakai, MD PhD, Ayaka Numata, MD PhD, Hidetoshi Itakura, MD, Akiyoshi Moriyama, MD, Shingo Kujime, MD   +10 more
doaj   +1 more source